MX2021012392A - Compuestos, composiciones y metodos. - Google Patents

Compuestos, composiciones y metodos.

Info

Publication number
MX2021012392A
MX2021012392A MX2021012392A MX2021012392A MX2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A MX 2021012392 A MX2021012392 A MX 2021012392A
Authority
MX
Mexico
Prior art keywords
methods
compositions
compounds
tautomer
stereoisomer
Prior art date
Application number
MX2021012392A
Other languages
English (en)
Inventor
Jianwen A Feng
Anthony A Estrada
Zachary K Sweeney
Vicente Fidalgo Javier De
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2021012392A publication Critical patent/MX2021012392A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción hace referencia, en general, a inhibidores de LRRK2, o una sal farmacéuticamente aceptable, análogo isotópicamente enriquecido, tautómero, estereoisómero, mezcla de estereoisómeros, profármaco o composición farmacéutica del mismos y métodos para su producción y uso.
MX2021012392A 2019-04-11 2020-04-10 Compuestos, composiciones y metodos. MX2021012392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832775P 2019-04-11 2019-04-11
PCT/US2020/027742 WO2020210684A1 (en) 2019-04-11 2020-04-10 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
MX2021012392A true MX2021012392A (es) 2021-11-12

Family

ID=72752101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012392A MX2021012392A (es) 2019-04-11 2020-04-10 Compuestos, composiciones y metodos.

Country Status (16)

Country Link
US (1) US20220220094A1 (es)
EP (1) EP3953348A4 (es)
JP (1) JP2022526015A (es)
KR (1) KR20210151887A (es)
CN (1) CN113939294A (es)
AR (1) AR118641A1 (es)
AU (1) AU2020272045A1 (es)
BR (1) BR112021020027A2 (es)
CA (1) CA3136447A1 (es)
EA (1) EA202192530A1 (es)
IL (1) IL287120A (es)
MA (1) MA55624A (es)
MX (1) MX2021012392A (es)
SG (1) SG11202111058XA (es)
WO (1) WO2020210684A1 (es)
ZA (1) ZA202107499B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834438B2 (en) 2017-12-20 2023-12-05 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
CN116120291B (zh) * 2023-04-11 2023-06-30 英矽智能科技(上海)有限公司 吲唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3124483T3 (pl) * 2010-11-10 2020-03-31 Genentech, Inc. Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2
CR20220182A (es) * 2016-06-16 2022-06-15 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592)
US20200157081A1 (en) * 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
US11834438B2 (en) * 2017-12-20 2023-12-05 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds

Also Published As

Publication number Publication date
KR20210151887A (ko) 2021-12-14
AR118641A1 (es) 2021-10-20
SG11202111058XA (en) 2021-11-29
EA202192530A1 (ru) 2022-03-15
EP3953348A4 (en) 2023-01-18
IL287120A (en) 2021-12-01
ZA202107499B (en) 2022-06-29
US20220220094A1 (en) 2022-07-14
CN113939294A (zh) 2022-01-14
AU2020272045A1 (en) 2021-10-28
BR112021020027A2 (pt) 2021-12-07
MA55624A (fr) 2022-02-16
EP3953348A1 (en) 2022-02-16
CA3136447A1 (en) 2020-10-15
TW202104213A (zh) 2021-02-01
JP2022526015A (ja) 2022-05-20
WO2020210684A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
SA520411222B1 (ar) مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق
CR20210426A (es) Compuestos, composiciones y métodos
EP4248965A3 (en) Compounds, compositions and methods
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
MX2021012392A (es) Compuestos, composiciones y metodos.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
TW202430153A (zh) 化合物、組成物及方法
PH12020500385A1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
WO2024130166A3 (en) Compounds, compositions, and methods
MY195679A (en) Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders
EA202192121A1 (ru) Соединения, составы и способы
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators
MA45389B1 (fr) Pyrimidin-2-ylamino -1h-pyrazols comme inhibiteurs de lrrk2 destinés au traitement de troubles neurodégénératifs